JP2020522261A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522261A5
JP2020522261A5 JP2019566609A JP2019566609A JP2020522261A5 JP 2020522261 A5 JP2020522261 A5 JP 2020522261A5 JP 2019566609 A JP2019566609 A JP 2019566609A JP 2019566609 A JP2019566609 A JP 2019566609A JP 2020522261 A5 JP2020522261 A5 JP 2020522261A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566609A
Other languages
English (en)
Japanese (ja)
Other versions
JP7168590B2 (ja
JP2020522261A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/035840 external-priority patent/WO2018226578A1/en
Publication of JP2020522261A publication Critical patent/JP2020522261A/ja
Publication of JP2020522261A5 publication Critical patent/JP2020522261A5/ja
Application granted granted Critical
Publication of JP7168590B2 publication Critical patent/JP7168590B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566609A 2017-06-05 2018-06-04 ネクチン4結合性タンパク質及びその使用方法 Active JP7168590B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515454P 2017-06-05 2017-06-05
US62/515,454 2017-06-05
PCT/US2018/035840 WO2018226578A1 (en) 2017-06-05 2018-06-04 Nectin-4-binding proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2020522261A JP2020522261A (ja) 2020-07-30
JP2020522261A5 true JP2020522261A5 (enExample) 2021-07-26
JP7168590B2 JP7168590B2 (ja) 2022-11-09

Family

ID=64566092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019566609A Active JP7168590B2 (ja) 2017-06-05 2018-06-04 ネクチン4結合性タンパク質及びその使用方法

Country Status (10)

Country Link
US (1) US11292837B2 (enExample)
EP (1) EP3635013A4 (enExample)
JP (1) JP7168590B2 (enExample)
KR (1) KR102723905B1 (enExample)
CN (2) CN111051345A (enExample)
BR (1) BR112019025513A2 (enExample)
CA (1) CA3065514A1 (enExample)
MX (1) MX2019014318A (enExample)
TW (1) TWI870338B (enExample)
WO (1) WO2018226578A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
TWI894130B (zh) 2018-12-03 2025-08-21 美商艾澤西公司 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法
CN110904073B (zh) * 2019-05-31 2020-12-01 江南大学 一种脂肪酶突变体及其在去污方面的应用
JP2022551537A (ja) * 2019-10-07 2022-12-09 ユニヴェルシテ デクス-マルセイユ ネクチン-4に対する特異性を有する抗体及びその使用
KR102280672B1 (ko) * 2019-12-20 2021-07-23 주식회사 베르티스 암의 진단용 조성물
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
WO2021257525A1 (en) * 2020-06-18 2021-12-23 Bioatla, Inc. Conditionally active anti-nectin-4 antibodies
EP4168039A4 (en) * 2020-06-19 2024-12-04 Agensys, Inc. MARKER FOR USE IN METHODS OF TREATING CANCER WITH ANTIBODY-DRUG CONJUGATES (ADC)
EP4208259A2 (en) * 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
GEAP202516662A (en) * 2020-09-16 2025-02-10 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Anti-nectin-4 antibody, conjugate including same, and application thereof
JP2024501121A (ja) * 2020-11-25 2024-01-11 イナート・ファルマ・ソシエテ・アノニム 癌の処置
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2022228406A1 (zh) * 2021-04-26 2022-11-03 江苏恒瑞医药股份有限公司 抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途
JP7820532B2 (ja) * 2022-01-12 2026-02-25 ナビ バイオ-セラピューティクス,インコーポレイティッド ネクチン細胞接着分子4に特異的な抗体及びその使用
US20250205353A1 (en) 2022-03-23 2025-06-26 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
WO2023198007A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Anti-nectin-4 antibodies and bispecific antibodies
WO2023198011A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Single domain anti-nectin-4 antibodies
WO2023198008A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Compositions and methods for treating cancer
EP4310101A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibodies and antibody-drug conjugates
WO2024059733A2 (en) * 2022-09-14 2024-03-21 Fred Hutchinson Cancer Center Chimeric antigen receptors binding nectin-4
KR102584898B1 (ko) * 2022-10-24 2023-10-04 연세대학교 산학협력단 자궁내막암 진단 방법 및 이를 이용한 키트
CN119101156A (zh) 2023-06-08 2024-12-10 江苏迈威康新药研发有限公司 结合Nectin-4的抗体及其用途
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン-4抗体及び抗体-薬物コンジュゲート
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
KR20250161707A (ko) * 2024-05-08 2025-11-18 아주대학교산학협력단 Nectin-2에 결합하는 항체 약물 접합체 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111076A1 (en) * 2004-05-12 2005-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (n4) as a marker for cancer prognosis
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
WO2010067487A1 (en) 2008-12-12 2010-06-17 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
MX347954B (es) * 2010-09-29 2017-05-19 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12.
EP3311173A2 (en) * 2015-06-18 2018-04-25 Thomas Mole Herd Methods of characterising cancer
JP6985252B2 (ja) * 2015-09-09 2021-12-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ネクチン−4に対する特異性を有する抗体及びその使用

Similar Documents

Publication Publication Date Title
JP2020522261A5 (enExample)
ES2692522T3 (es) Anticuerpo anti-cMet y su utilización para la detección y el diagnóstico del cáncer
RU2425841C2 (ru) Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
RU2018108048A (ru) Новые анти-pd-1 антитела
JP2021500916A5 (enExample)
IL261666B2 (en) Binding proteins and methods of use thereof
JP2013506428A5 (enExample)
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2014512809A5 (enExample)
JP2017149720A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
WO2014089209A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
JP2017507131A5 (enExample)
JP2015503909A5 (enExample)
JP2014518630A5 (enExample)
JP2024029261A5 (enExample)
JP2018525320A5 (enExample)
JP2018508467A (ja) 抗il−34抗体
EP3954999B9 (en) Compositions and methods for detecting and treating ovarian cancer
CA3058263C (en) Compositions and methods for detecting prostate cancer
JP2019048895A5 (enExample)
CN109069606A (zh) 干扰素β抗体及其用途
JP2017524362A5 (enExample)